ClinicalTrials.gg
CompletedNCT07256288Updated Dec 1, 2025

A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects

A Phase 1 interventional study of EA5 and Placebo in Healthy Volunteers, sponsored by Shanghai Lanyi Therapeutics Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Shanghai Lanyi Therapeutics Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled May 2023, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, double-blind, placebo-controlled, dose-escalating Phase Ia clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of EA5 in healthy adult subjects.

Read the detailed description

The study plans to enroll up to 28 subjects. Its primary purpose is to conduct a preliminary assessment of the exposure, safety, and pharmacokinetic profile of EA5 in humans, thereby informing the confirmation or adjustment of the formal trial design. The trial is structured into a pilot phase and a formal phase, encompassing a total of five planned dose cohorts: the pilot trial involves two dose groups (90 mg and 180 mg), each with 2 subjects receiving the active drug; the formal trial consists of three dose groups (360 mg, 720 mg, and 1440 mg), where participants are randomized in a 3:1 ratio (6 subjects receiving the active drug EA5 and 2 subjects receiving placebo per cohort), administered via intravenous (IV) infusion.A 57-day observation period was performed for safety, pharmacokinetic, and pharmacodynamic assessments after study drug administration. Antidrug antibody (ADA) levels were monitored in study participants for the duration of the 57-day follow-up period.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Lanyi Therapeutics Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects aged 18 to 55 years (inclusive), regardless of gender.
  • Body weight ≥50 kg (male) or ≥45 kg (female), and a (BMI) between 18 and 28 kg/m² (inclusive).
  • Must have received the meningococcal polysaccharide vaccine MenACWY (containing serogroups A, C, W, and Y) at least two weeks prior to dosing.
  • Subjects must be able to communicate effectively with the investigator and are expected to comply with the study procedures as defined in the protocol.
  • Subjects must be in good general health, as judged by the investigator based on medical history, physical examination, vital signs, (ECG), chest X-ray, abdominal ultrasound, and laboratory test results.
  • Male subjects agree to use effective (vasectomy, abstinence, or condom) from screening until 6 months after the final study intervention. Female subjects must have a negative blood pregnancy test at screening and baseline. Throughout the study and for 6 months thereafter, all subjects and their partners (if of ) must use highly effective non-pharmacological contraception.
  • Subjects must provide written voluntarily before any study-specific procedures are performed.
  • Systolic and diastolic blood pressure must be within the normal range, or exhibit abnormalities deemed clinically insignificant by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of severe drug allergy; or a clear history of allergy and/or known allergy to the product or any of its , which in the opinion of the investigator, renders the subject unsuitable for participation in the study.
  • Prior history of splenectomy.
  • History of pulmonary tuberculosis.
  • Congenital or acquired complement deficiency (e.g., hypocomplementemia).
  • Any to antibiotic prophylaxis (e.g., beta-lactam antibiotics, ciprofloxacin) for meningococcal infection
  • Positive test for virus (HCV) antibody, (HIV) antibody, treponemal antibody (TP-Ab), or virus (HBV) surface antigen (HBsAg) at screening
  • Presence of symptoms or a significant history of any major disease, including but not limited to cardiac, hepatic, renal, other acute or chronic gastrointestinal or respiratory diseases; hematological, endocrine, neurological, psychiatric disorders; or any other disease or physiological condition that could interfere with the interpretation of the study results.
  • Participation in any clinical trial involving an investigational drug or medical device within 3 months prior to screening, or within 5 half-lives of the previous investigational drug prior to screening (whichever is longer)
  • Blood loss or donation > 400 mL within 3 months prior to screening, or > 200 mL within 4 weeks prior to screening, or intention to donate blood during the study period
  • Average cigarette smoking of ≥5 cigarettes per day within 3 months prior to the study
  • Alcohol abuse or regular alcohol consumption exceeding 14 units per week within 6 months prior to screening (1 unit ≈ 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or a positive alcohol breath test at screening.
  • History of drug abuse or a positive urine drug screen at screening
  • Undergone surgery or received blood or blood product transfusion within 1 month prior to screening。
  • Administration of any live or within 1 month prior to the first dose。
  • Use of any prescription drugs, over-the-counter medications, herbal medicines, or vitamins within 14 days or 5 half-lives (whichever is longer) prior to screening。
  • Presence of any active infection (viral, bacterial, or fungal), including herpes zoster or herpes simplex, within 14 days prior to dosing.
  • History of fever (≥38°C) within 7 days prior to the first dose.
  • Female subjects who are pregnant or lactating, or who have engaged in unprotected sexual intercourse within 14 days prior to the study.
  • Inability to complete the study for any other reason, or considered by the investigator to be unsuitable for inclusion.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    EA5 90mg

    EA5 was administered intravenously.

    Drug: EA5

  • Experimental
    EA5 180mg

    EA5 was administered intravenously.

    Drug: EA5

  • Experimental
    EA5 360mg

    EA5 was administered intravenously.

    Drug: EA5 · Drug: Placebo

  • Experimental
    EA5 720mg

    EA5 was administered intravenously.

    Drug: EA5 · Drug: Placebo

  • Experimental
    EA5 1440mg

    EA5 was administered intravenously.

    Drug: EA5 · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo was administered intravenously.

    Drug: EA5

Interventions

  • DrugEA5

    All doses of EA5 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters.

  • DrugPlacebo

    All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Day 57

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of EA5

    Blood samples were collected for analysis of Cmax

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  2. Time To Maximum Observed Serum Concentration (Tmax) of EA5

    Blood samples were collected for analysis of Tmax

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  3. Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of EA5

    Blood samples were collected for analysis of AUC0-t

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  4. Area Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of EA5

    Blood samples were collected for analysis of AUCinf

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  5. Terminal Elimination Rate Constant (λz) of Serum EA5

    Blood samples were collected for analysis of λz

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  6. Terminal Elimination Half-life (t½) of Serum EA5

    Blood samples were collected for analysis of t½

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  7. Total Clearance (CL) of EA5

    Blood samples were collected for analysis of CL

    Time frame: 30 minutes predose, 5 minutes, 1, 2, 6, 24, hours postdose, then at Days 3, 4, 8, 15, 29, 43, 57

  8. Percent Change From Baseline in Free Complement Component 5 (C5)

    Blood samples were collected for analysis of free C5 concentrations.

    Time frame: Baseline, Day 57

  9. Percent Change From Baseline in Total Complement C5

    Blood samples were collected for analysis of total C5 concentrations.

    Time frame: Baseline, Day 57

  10. Percent Change From Baseline in determination of terminal complement activity in serum

    Blood samples were collected for analysis of determination of terminal complement activity

    Time frame: Baseline, Day 57

  11. Percentage of Participants With Positive Anti-Drug Antibody (ADA)

    lood samples were collected to evaluate antibody response through development of ADAs.

    Time frame: Baseline up to Day 57

07

Study locations

1 site
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 1, 2025
StartActual
May 31, 2023
Primary completionActual
Aug 1, 2024
CompletionActual
Aug 1, 2024
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07256288
Lead sponsor
Shanghai Lanyi Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
May 31, 2023
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024
Last update
Dec 1, 2025

Study contacts

Wei Hu, Professor
principal investigator · The Second Hospital of Anhui Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EA5

Start the discussion